

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: Bandman, Olga
 Lal, Preeti
 Shah, Purvi

(ii) TITLE OF THE INVENTION: NEW HUMAN INTEGRAL MEMBRANE PROTEIN

(iii) NUMBER OF SEQUENCES: 3

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Incyte Pharmaceuticals, Inc.
 (B) STREET: 3174 Porter Drive
 (C) CITY: Palo Alto
 (D) STATE: CA
 (E) COUNTRY: USA
 (F) ZIP: 94304

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette
 (B) COMPUTER: IBM Compatible
 (C) OPERATING SYSTEM: DOS
 (D) SOFTWARE: FastSEQ for Windows Version 2.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
 (B) FILING DATE:
 (C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:
 (B) FILING DATE:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Billings, Lucy J.
 (B) REGISTRATION NUMBER: 36,749
 (C) REFERENCE/DOCKET NUMBER: PF-0339 US

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 415-855-0555
 (B) TELEFAX: 415-845-4166

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 266 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: BRAINOT03
 (B) CLONE: 662708

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met Val Lys Ile Ser Phe Gln Pro Ala Val Ala Gly Ile Lys Gly Asp
 1 5 10 15
 Lys Ala Asp Lys Ala Ser Ala Ser Ala Pro Ala Pro Ala Ser Ala Thr
 20 25 30
 Glu Ile Leu Leu Thr Pro Ala Arg Glu Glu Gln Pro Pro Gln His Arg
 35 40 45
 Ser Lys Arg Gly Gly Ser Val Gly Gly Val Cys Tyr Leu Ser Met Gly
 50 55 60
 Met Val Val Leu Leu Met Gly Leu Val Phe Ala Ser Val Tyr Ile Tyr

65	70	75	80
Arg	Tyr	Phe	Phe
Leu	Leu	Ala	Gln
Leu	Ala	Arg	Asp
85	90	95	Cys
Gly	Val	Tyr	Glu
Asp	Ser	Ser	Ser
Leu	Leu	Gln	Val
100	105	110	Met
Glu	Glu	Glu	Asp
Asp	Val	Lys	Ile
115	120	125	Tyr
Ile	Asn	Val	Pro
130	135	140	Val
Ile	His	Asp	Phe
145	150	155	Gly
Lys	Cys	Tyr	Leu
160	165	170	Asp
Asn	Phe	Trp	Glu
180	185	190	Leu
Gln	Thr	Tyr	Leu
195	200	205	Met
Asp	Lys	Ile	Gln
210	215	220	Glu
Asp	Thr	Tyr	Arg
225	230	235	Leu
Arg	Gly	Ala	Arg
245	250	255	Arg
Val	Val	Glu	Asn
260	265		Phe

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1181 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) BRAINOT03
- (B) CLONE: 662708

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CGAGCGGGAT	CCAAACTTCC	GGTGCCTGCA	GAGCTCGGAG	CGGGCGGAGGC	AGAGACCGAG	60
GCTGCACCGG	CAGAGGCTGC	GGGGCGGACG	CGCAGGCGCG	CGCAGCCATG	GTGAAGATTA	120
GCTTCCAGCC	CGCCGTGGCT	GGCATCAAGG	GCGACAAGGC	TGACAAGGCG	TGGCGTCGG	180
CCCCTGCGCC	GGCCTCGGCC	ACCGAGATCC	TGCTGACGCC	GGCTAGGGAG	GAGCAGCCCC	240
CACAACATCG	ATCCAAGAGG	GGGGGCTCAG	TGGGCGGCCGT	GTGCTACCTG	TCGATGGCA	300
TGGTCGTGCT	GCTCATGGGC	CTCGTGTTCG	CCTCTGTCTA	CATCTACAGA	TACTTCTTTC	360
TTGCACAGCT	GGCCCCGAGAT	AACCTCTTCC	GCTGTGGTGT	GCTGTATGAG	GACTCCCTGT	420
CCTCCCGAGGT	CCGGACTCTAG	ATGGAGCTGG	AAGAGGGATGT	GAAAATCTAC	CTCGACCGAGA	480
ACTACGAGCG	CATCAACGTG	CCTGTGCCCC	AGTTTGGCGG	CGGTGACCC	GCAGACATCA	540
TCCATGACTT	CCAGCGGGGT	CTGACTGCGT	ACCATGATAT	CTTGGACAAG	TGCTATGTCA	600
TCGAACCTCAA	CACCACCAT	GTGCTGCCCC	CTCGCAACTT	CTGGGAGCTC	CTCATGAAACG	660
TGAAGAGGGG	GACCTACCTG	CCGCAGACGT	ACATCATCCA	GGAGGGAGATG	GTGGTCACGG	720
AGCATGTCAG	TGACAAGGGAG	GCCCTGGGGT	CCTTCATCTA	CCACCTGTGC	AACGGGAAAG	780
ACACCTACCG	GCTCCGGCGC	CGGGCAACGC	GGAGGGCGGAT	CAACAAGCGT	GGGGCCAAGA	840
ACTGCAATGC	CATCCGCCAC	TTCGAGAAC	CCTTCGTGGT	GGAGACGCTC	ATCTGCGGGG	900
TGGTGTGAGG	CCCTCCTCCC	CCAGAACCCC	CTGCCGTGTT	CCTCTTTCT	TCTTCCGGC	960
TGCTCTCTGG	CCCTCCTCCT	TCCCCCTGCT	TAGCTTGTAC	TTTGGACGCG	TTTCTATAGA	1020
GGTGACATGT	CTCTCCATTC	CTCTCCAACC	CTGCCACCT	CCCTGTACCA	GAGCTGTGAT	1080
CTCTCGGTGG	GGGGCCCATC	TCTGCTGACC	TGGGTGTGGC	GGAGGGAGAG	GCGATGCTGC	1140
AAAGTGTGTTT	CTGTGTCCCA	CTGTCTTGAA	GCTGGGCCTG	C		1181

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 263 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

(A) LIBRARY: GenBank

(B) CLONE: 624778

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Val Lys Ile Ala Phe Asn Thr Pro Thr Ala Val Gln Lys Glu Glu
 1 5 10 15
 Ala Arg Gln Asp Ile Glu Ala Leu Val Ser Arg Thr Val Arg Ala Gln
 20 25 30
 Ile Leu Thr Gly Lys Glu Leu Arg Val Val Pro Gln Glu Lys Asp Gly
 35 40 45
 Ser Ser Gly Arg Cys Met Leu Thr Leu Leu Gly Leu Ser Phe Ile Leu
 50 55 60
 Ala Gly Leu Ile Val Gly Gly Ala Cys Ile Tyr Lys Tyr Phe Met Pro
 65 70 75 80
 Lys Ser Thr Ile Tyr His Gly Glu Met Cys Phe Phe Asp Ser Glu Asp
 85 90 95
 Pro Val Asn Ser Ile Pro Gly Gly Glu Pro Tyr Phe Leu Pro Val Thr
 100 105 110
 Glu Glu Ala Asp Ile Arg Glu Asp Asp Asn Ile Ala Ile Ile Asp Val
 115 120 125
 Pro Val Pro Ser Phe Ser Asp Ser Asp Pro Ala Ala Ile Ile His Asp
 130 135 140
 Phe Glu Lys Gly Met Thr Ala Tyr Leu Asp Leu Leu Leu Gly Asn Cys
 145 150 155 160
 Tyr Leu Met Pro Leu Asn Thr Ser Ile Val Met Thr Pro Lys Asn Leu
 165 170 175
 Val Glu Leu Phe Gly Lys Leu Ala Ser Gly Lys Tyr Leu Pro His Thr
 180 185 190
 Tyr Val Val Arg Glu Asp Leu Val Ala Val Glu Glu Ile Arg Asp Val
 195 200 205
 Ser Asn Leu Gly Ile Phe Ile Tyr Gln Leu Cys Asn Asn Arg Lys Ser
 210 215 220
 Phe Arg Leu Arg Arg Arg Asp Leu Leu Leu Gly Phe Asn Lys Arg Ala
 225 230 235 240
 Ile Asp Lys Cys Trp Lys Ile Arg His Phe Pro Asn Glu Phe Ile Val
 245 250 255
 Glu Thr Lys Ile Cys Gln Glu
 260